TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
Read original at benzingaStocks · News reference
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 2:01 PM
- Checked
- Aug 27, 2026, 2:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.
Read original at benzingaCitizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
Read original at benzinga